E-LIB Suche - Ergebnisse für: Haslam, Alyson

1

INDIGO: Example of inappropriate crossover and why PFS cann..:

Zugman, Miguel ; Haslam, Alyson ; Prasad, Vinay
Journal of Cancer Policy. 40 (2024) - p. 100476 , 2024

Link: https://doi.org/10.1016/..

2

Justification for unequal allocation ratios in clinical tri..:

Nay, Joshua ; Haslam, Alyson ; Prasad, Vinay
Contemporary Clinical Trials. 139 (2024) - p. 107484 , 2024

Link: https://doi.org/10.1016/..

3

An empirical analysis of overall survival in drug approvals..:

Elbaz, Josh ; Haslam, Alyson ; Prasad, Vinay
Cancer Medicine. 13 (2024) 8 - p. , 2024

Link: https://doi.org/10.1002/..

4

CDK4/6 inhibitors as adjuvant therapy in early breast cance..:

Haslam, Alyson ; Ranganathan, Sruthi ; Prasad, Vinay.
European Journal of Cancer. 207 (2024) - p. 114192 , 2024

Link: https://doi.org/10.1016/..

5

Assessing Patient Risk, Benefit, and Outcomes in Drug Devel..:

Crotty, Patrick ; Kari, Karim ; Hughes, Griffin K....
Targeted Oncology. 19 (2024) 2 - p. 161-173 , 2024

Link: https://doi.org/10.1007/..

6

The importance of falsification endpoints in observational ..:

Høeg, Tracy B. ; Haslam, Alyson ; Prasad, Vinay
Epidemiology and Infection. 152 (2024) - p. , 2024

Link: https://doi.org/10.1017/..

7

Recall of ibrutinib and issues with therapeutic approval:

Lipfert, Colton ; Kim, Myung Sun ; Haslam, Alyson.
BMJ Oncology. 3 (2024) 1 - p. e000418 , 2024

Link: https://doi.org/10.1136/..

8

Assessing Patient Risk, Benefit, and Outcomes in Drug Devel..:

Hunter Hall, Rafe ; Wright, Carson L. ; Hughes, Griffin K....
Clinical Therapeutics. 46 (2024) 6 - p. e107-e113 , 2024

Link: https://doi.org/10.1016/..

9

Social media engagement of supportive care publications in ..:

Ranganathan, Sruthi ; Benjamin, David J. ; Haslam, Alyson.
Journal of Cancer Policy. 41 (2024) - p. 100491 , 2024

Link: https://doi.org/10.1016/..

10

Financial conflicts of interest among presenters, panellist..:

Miller, Sarah L. ; Haslam, Alyson ; Prasad, Vinay
European Journal of Clinical Investigation. 54 (2024) 6 - p. , 2024

Link: https://doi.org/10.1111/..

11

Assessing patient risk, benefit and outcomes in drug develo..:

Dennis, Brody ; Bratten, Chance ; Hughes, Griffin K...
BMJ Oncology. 3 (2024) 1 - p. e000229 , 2024

Link: https://doi.org/10.1136/..

12

The landscape of checkpoint inhibitors in oncology:

Haslam, Alyson ; Kim, Myung Sun ; Elbaz, Josh.
European Journal of Cancer. 209 (2024) - p. 114240 , 2024

Link: https://doi.org/10.1016/..

13

Publication of observational studies making claims of causa..:

Haslam, Alyson ; Prasad, Vinay
Contemporary Clinical Trials Communications. 40 (2024) - p. 101327 , 2024

Link: https://doi.org/10.1016/..

14

Clinical benefit, reimbursement outcomes, and prices of FDA..:

Jenei, Kristina ; Gentilini, Arianna ; Haslam, Alyson.
The Lancet Oncology. 25 (2024) 8 - p. 979-988 , 2024

Link: https://doi.org/10.1016/..

15

Assessing patient risk, benefit, and outcomes in drug devel..:

Khan, Adam ; Khan, Hassan ; Hughes, Griffin K....
Cancer Medicine. 13 (2024) 9 - p. , 2024

Link: https://doi.org/10.1002/..